Zhou, Hang http://orcid.org/0000-0002-7694-6391
Kember, Rachel L. http://orcid.org/0000-0001-8820-2659
Deak, Joseph D. http://orcid.org/0000-0002-0540-6080
Xu, Heng
Toikumo, Sylvanus
Yuan, Kai
Lind, Penelope A.
Farajzadeh, Leila
Wang, Lu
Hatoum, Alexander S.
Johnson, Jessica
Lee, Hyunjoon
Mallard, Travis T. http://orcid.org/0000-0002-3265-3001
Xu, Jiayi http://orcid.org/0000-0001-6379-386X
Johnston, Keira J. A. http://orcid.org/0000-0002-1370-3149
Johnson, Emma C. http://orcid.org/0000-0003-0394-777X
Nielsen, Trine Tollerup
Galimberti, Marco http://orcid.org/0000-0001-6052-156X
Dao, Cecilia
Levey, Daniel F. http://orcid.org/0000-0001-8431-9569
Overstreet, Cassie
Byrne, Enda M.
Gillespie, Nathan A.
Gordon, Scott http://orcid.org/0000-0001-7623-328X
Hickie, Ian B. http://orcid.org/0000-0001-8832-9895
Whitfield, John B. http://orcid.org/0000-0002-1103-0876
Xu, Ke http://orcid.org/0000-0002-6472-7052
Zhao, Hongyu http://orcid.org/0000-0003-1195-9607
Huckins, Laura M. http://orcid.org/0000-0002-5369-6502
Davis, Lea K.
Sanchez-Roige, Sandra
Madden, Pamela A. F.
Heath, Andrew C.
Medland, Sarah E.
Martin, Nicholas G. http://orcid.org/0000-0003-4069-8020
Ge, Tian
Smoller, Jordan W.
Hougaard, David M. http://orcid.org/0000-0001-5928-3517
Børglum, Anders D. http://orcid.org/0000-0001-8627-7219
Demontis, Ditte http://orcid.org/0000-0001-9124-2766
Krystal, John H. http://orcid.org/0000-0001-6952-1726
Gaziano, J. Michael
Edenberg, Howard J. http://orcid.org/0000-0003-0344-9690
Agrawal, Arpana http://orcid.org/0000-0002-0313-793X
Zhao, Hongyu
Justice, Amy C. http://orcid.org/0000-0003-0139-5502
Stein, Murray B. http://orcid.org/0000-0001-9564-2871
Kranzler, Henry R. http://orcid.org/0000-0002-1018-0450
Gelernter, Joel http://orcid.org/0000-0002-4067-1859
,
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R21 CA252916)
U.S. Department of Health & Human Services | NIH | National Institute on Alcohol Abuse and Alcoholism (U54 AA027989, K01 AA02829, T32 AA028259, K01 AA030083, P50 AA12870, R01 AA026364)
Brain and Behavior Research Foundation (27835)
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (K01 DA051759, DP1 DA054394, R01 DA054869)
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (R01 MH124839, U01 MH109514, R01 MH124851)
U.S. Department of Veterans Affairs (I01BX003341, I01CX001849)
Article History
Received: 24 January 2023
Accepted: 18 October 2023
First Online: 7 December 2023
Competing interests
: H.R.K. is a member of advisory boards for Dicerna Pharmaceuticals, Sophrosyne Pharmaceuticals, Enthion Pharmaceuticals and Clearmind Medicine; a consultant to Sobrera Pharmaceuticals; the recipient of research funding and medication supplies for an investigator-initiated study from Alkermes; and a member of the American Society of Clinical Psychopharmacology’s Alcohol Clinical Trials Initiative, which was supported in the past 3 years by Alkermes, Dicerna, Ethypharm, Lundbeck, Mitsubishi, Otsuka and Pear Therapeutics. M.B.S. has in the past 3 years been a consultant for Actelion, Acadia Pharmaceuticals, Aptinyx, Bionomics, BioXcel Therapeutics, Clexio, EmpowerPharm, Epivario, GW Pharmaceuticals, Janssen, Jazz Pharmaceuticals, Roche/Genentech and Oxeia Biopharmaceuticals. M.B.S. has stock options in Oxeia Biopharmaceuticals and Epivario. He also receives payment from the following entities for editorial work: Biological Psychiatry (published by Elsevier), Depression and Anxiety (published by Wiley) and UpToDate. J.G. and H.R.K. hold United States patent 10,900,082 titled: ‘Genotype-guided dosing of opioid agonists,’ issued 26 January 2021. J.G. is paid for his editorial work on the journal Complex Psychiatry. J.H.K. has consulting agreements (less than US$10,000 per year) with the following: AstraZeneca Pharmaceuticals, Biogen, Idec, MA, Biomedisyn Corporation, Bionomics Limited (Australia), Boehringer Ingelheim International, COMPASS Pathways Limited (United Kingdom), Concert Pharmaceuticals Inc., Epiodyne Inc., EpiVario Inc., Heptares Therapeutics Limited (United Kingdom), Janssen Research & Development, Otsuka America, Pharmaceutical Inc., Perception Neuroscience Holdings Inc., Spring Care Inc., Sunovion Pharmaceuticals Inc., Takeda Industries and Taisho Pharmaceutical Co. Ltd. J.H.K. serves on the scientific advisory boards of Bioasis Technologies Inc., Biohaven Pharmaceuticals, BioXcel Therapeutics Inc. (Clinical Advisory Board), BlackThorn Therapeutics Inc., Cadent Therapeutics (Clinical Advisory Board), Cerevel Therapeutics LLC., EpiVario Inc., Lohocla Research Corporation, PsychoGenics Inc.; is on the board of directors of Inheris Biopharma Inc.; has stock options with Biohaven Pharmaceuticals Medical Sciences, BlackThorn Therapeutics Inc., EpiVario Inc. and Terran Life Sciences; and is editor of Biological Psychiatry with income greater than $10,000. I.B.H. is the co-director of Health and Policy at the Brain and Mind Centre University of Sydney. The Brain and Mind Centre operates an early intervention youth services at Camperdown under contract to Headspace. He is the Chief Scientific Advisor to, and a 3.2% equity shareholder in, InnoWell Pty Ltd. InnoWell was formed by the University of Sydney (45% equity) and PwC (Australia; 45% equity) to deliver the $30 M Australian Government-funded Project Synergy (2017–20; a 3 year program for the transformation of mental health services) and to lead transformation of mental health services internationally through the use of innovative technologies. J.W.S. is a member of the Leon Levy Foundation Neuroscience Advisory Board, the Scientific Advisory Board of Sensorium Therapeutics (with equity) and has received grant support from Biogen Inc. He is principal investigator of a collaborative study of the genetics of depression and bipolar disorder sponsored by 23andMe for which 23andMe provides analysis time as in-kind support but no payments. D.D. has received a speaker fee from Medici Nordic. All other authors report no biomedical financial interests or potential conflicts of interest.